Professor Freemont is Head of the Section of Structural and Synthetic Biology in the Department of Infectious Disease at Imperial College. The Section is based in South Kensington Sir Alexander Fleming Building and focuses on the molecular mechanisms of human disease and infection using the tools of integrated structural biology comprising X-ray crystallography, Cryo-EM and associated biophysical, spectroscopic and cellular techniques. The Section is also leading the London Consortium for Cryo-EM (LonCEM) with partners Kings College, Institute of Cancer Research, Queen Mary University and the Francis Crick Institute. In addition the Section also has research programs in synthetic biology focused on automation, cell free systems, microbiome engineering, low cost viral and pathogenic biosensors and novel natural product discovery. Please go to the Structural and Synthetic Biology Section website for news, up-to-date research summaries, a list of job opportunities, and information on lab members.
Professor Freemont is also co-founder of the Imperial College Centre for Synthetic Biology (2009) and co-founder/co-director of the National UK Innovation and Knowledge Centre for Synthetic Biology (SynbiCITE; since Oct 2013) at Imperial College London. The Centre aims to enable synthetic biology research in application areas like biosensors, biosynthesis, bioprocessing and metabolic and genome engineering and enable the translation of new synthetic biology technologies into start-ups, SME's and industry. Previous to this he was head of the Division of Molecular Biosciences at Imperial (now the Department of Life Sciences), and head of the Centre for Structural Biology having joined Imperial from Cancer Research UK London Research Institute (now known as the Francis Crick Institute) where he was a Principal Scientist. His research interests span from understanding molecular mechanisms associated with human disease and infection using structural molecular biology techniques to the development of synthetic biology cell-free and platform technologies for healthcare applications.
et al., 2020, Author Correction: A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics., Nat Commun, Vol:11
et al., 2020, A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics, Nature Communications, Vol:11, ISSN:2041-1723, Pages:1-11
et al., 2020, SARS-CoV-2 infection, clinical features and outcome of COVID-19 in United Kingdom nursing homes, Journal of Infection, Vol:81, ISSN:0163-4453, Pages:411-419
Kelwick R, Webb A, Freemont P, 2020, Biological materials: the next frontier for cell-free synthetic biology, Frontiers in Bioengineering and Biotechnology, Vol:8, ISSN:2296-4185